Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

932 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team. Molina JM, et al. Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8. Lancet. 2008. PMID: 18722869 Clinical Trial.
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, et al. Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12. Int J Epidemiol. 2012. PMID: 23148105 Free PMC article.
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Rotger M, et al. Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26. Clin Infect Dis. 2013. PMID: 23532479 Free PMC article.
Associations between immune depression and cardiovascular events in HIV infection.
Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Sabin CA, et al. AIDS. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3. AIDS. 2013. PMID: 23842128
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team. Clotet B, et al. Among authors: antinori a. Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1. Lancet. 2014. PMID: 24698485 Clinical Trial.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Among authors: antinori a. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
932 results